You are here: Industry Insights > Market News > Lupin launches Meloxicam Capsules

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Lupin launches Meloxicam Capsules

expresspharmaDecember 29, 2020

Tag: lupin , Meloxicam Capsules , osteoarthritis , FDA

Favorites

Lupin announced the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration (US FDA).

Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, and indicated for the management of osteoarthritis (OA) pain.

Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $11 million in the US (IQVIA MAT October 2020).

Previous:NASSCOM, BIRAC launch ‘JAN-Care’ challenge to scale health tech innovation

Next:SEC asks Bharat Serums to revise phase I/II trial protocols for equine antiserum to treat COVID-19

The life science and biotech PR distribution service

Biotech NewswireMay 06, 2024

Alfred Merz, PhD, has been appointed as Chief Operating Officer effective May 1st, 2024.

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

PharmaSourcesApril 28, 2024

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Biotech NewswireApril 26, 2024

Lupin launches Meloxicam Capsules | Pharmasources.com

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

PharmaSourcesApril 18, 2024

The study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP.

Lupin launches Meloxicam Capsules

Related News

The life science and biotech PR distribution service

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

You may like